Logo

Alchemedicine Entered into an Exclusive License Agreement with Asahi Kasei Pharma for Endothelin A Receptor Antagonist to Treat Chronic Kidney Disease

Share this
Alchemedicine Entered into an Exclusive License Agreement with Asahi Kasei Pharma for Endothelin A Receptor Antagonist to Treat Chronic Kidney Disease

Alchemedicine Entered into an Exclusive License Agreement with Asahi Kasei Pharma for Endothelin A Receptor Antagonist to Treat Chronic Kidney Disease

Shots:

  • Alchemedicine to receive ~$5.35B up front & is eligible to receive development, regulatory & commercial milestones along with royalty. The companies collaborated to develop & commercialize Alchemedicine’s selective Endothelin A receptor antagonist which is currently in the preclinical stage
  • Kasei Pharma obtains an exclusive right globally to develop and commercialize selective Endothelin A receptor antagonist
  • The selective endothelin A receptor antagonist is a small molecule that was developed from Alchemedicine’s HiSAP1 platform for a variety of difficult-to-control refractory diseases incl. CKD & demonstrated potent inhibition & high selectivity as well as exceptional efficacy in animal models of CKD

Ref: Asahi Kasei Pharma | Image: Alchemedicine

Click here to­ read the full press release 

Neha

Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions